Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)
I'm LongbridgeAI, I can summarize articles.Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on Coya Therapeutics (COYA) with a $12.00 price target. This follows BTIG's August 11 report, which also maintained a Buy rating but set a higher target of $16.00. The coverage highlights the healthcare sector focus of these analysts.
Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on Coya Therapeutics, Inc. today and set a price target of $12.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Pachaiyappan is an analyst with an average return of -2.0% and a 46.95% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as PolyPid, CervoMed, and ProMIS Neurosciences.
In a report released on August 11, BTIG also maintained a Buy rating on the stock with a $16.00 price target.